The Shenzhen University of Advanced Technology (SUAT), in collaboration with Fosun Pharma and Huawei Technologies, has launched the GBA AI+ Medical Collaborative Innovation Center in Guangming District, as announced by the university on its official WeChat account Wednesday.
This initiative aims to revolutionize the application of AI technology in the medical and pharmaceutical sectors in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
The collaborative effort between the three parties will focus on creating an integrated research platform that merges AI technology with biomedicine, diagnostics, and medical processes. Over three years, the partners plan to develop five AI-based sub-platforms, including AI-assisted drug design, translational medicine, clinical trials, medical decision-making, and medical equipment innovation.
During a launch event Saturday, Chen Youhai, dean of the Faculty of Pharmaceutical Sciences at SUAT, detailed SUAT’s activity in the AI sector, including the development of the Artificial Intelligence Research Institute, the AI Pharmaceutical Center, and the Intelligence Computing Center. Executives from Fosun Pharma discussed the company’s AI strategies and its ongoing collaborations with SUAT and Huawei to advance the AI collaborative innovation center.
The construction goals of the AI innovation center align well with Guangming District’s emphasis on innovation collaboration and industrial integration, district officials said at the event, adding that the district supports the construction of the AI innovation center and will provide comprehensive services related to policies, space, and equipment.
Fan Jianping, SUAT’s president, proposed a model focusing on interdisciplinary education between AI and pharmaceuticals to cultivate professionals who are proficient in both AI and medicine.
The center aims to provide top-tier AI medical services to local pharmaceutical enterprises, universities, and research institutions, thereby accelerating the development and commercialization of innovative drugs and medical technologies in China.
分享到：
,https://www.sz.gov.cn/en_szgov/news/latest/content/post_11976274.html